Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17281025 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Non-Final OA | NORTH CAROLINA STATE UNIVERSITY |
| 18178086 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | Non-Final OA | AMGEN INC. |
| 17609363 | MODULATING ANTIBODY EFFECTOR FUNCTIONS | Final Rejection | AMGEN INC. |
| 17762576 | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy | Final Rejection | Bristol-Myers Squibb Company |
| 17925574 | B7H3-TARGETING PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17295747 | METHODS OF OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS | Final Rejection | Board of Regents, The University of Texas System |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | Final Rejection | Iovance Biotherapeutics, Inc. |
| 17460986 | System and Process for Production of Isotopes and Isotope Compositions | Non-Final OA | Battelle Memorial Institute |
| 18034037 | ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS | Non-Final OA | Vrije Universiteit Brussel |
| 18012900 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | Non-Final OA | Cedars-Sinai Medical Center |
| 18667681 | METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY | Non-Final OA | INVEN2 AS |
| 17262105 | TARGET CELL SPECIFIC CYTOSOL-PENETRATING ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18245114 | ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND USES THEREOF | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 18032086 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18471357 | Chimeric Antigen Receptor Specific for Folate Receptor 1 | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18549446 | Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof | Non-Final OA | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
| 18279193 | DEVELOPMENT OF COVID-19 VACCINE USING A DUAL TLR LIGAND LIPOSOME ADJUVANT | Non-Final OA | Anna Pomés |
| 17798879 | PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY | Final Rejection | Orano Med |
| 17585356 | TREATMENT OF KIDNEY FAILURE USING EX VIVO REPROGRAMMED IMMUNE CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | Non-Final OA | University of Leicester |
| 18016279 | ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | Non-Final OA | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
| 17280403 | ANTIBODY COMPOSITION | Final Rejection | Kyowa Kirin Co., Ltd. |
| 17413965 | IMPROVED CELL-TARGETING BINDING MOLECULE | Non-Final OA | Sapreme Technologies B.V. |
| 17812155 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | Non-Final OA | SYNAFFIX B.V. |
| 18043159 | STABLE PHARMACEUTICAL FORMULATION, VIAL, CARTRIDGE, PRE-FILLED SYRINGE AND AUTO-INJECTOR COMPRISING THE SAME | Final Rejection | CELL TRION INC. |
| 17284091 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | Non-Final OA | Hangzhou DAC Biotech Co., Ltd. |
| 18003113 | ANTI-HMMW ANTIBODY, COMPOSITION COMPRISING SAME, AND NUCLEIC ACID MOLECULE ENCODING SAME, AND USE THEREOF | Non-Final OA | NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD. |
| 18011801 | COMBINATION THERAPY COMPRISING ANTI-CD137 ANTIBODIES | Final Rejection | Adagene PTE. LTD. |
| 18002655 | BINDING PROTEIN HAVING H2L2 AND HCAB STRUCTURES | Non-Final OA | HARBOUR BIOMED (SHANGHAI) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy